NCT04644822已完成3 期
A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 4
- 主要终点
- Primary Endpoint:
研究概览
简要总结
This is a prospective, Phase 3 non-randomized, open label, multi-centre clinical trial to assess the safety and efficacy of [18F]PSMA-1007 Injection (investigational product or IP) in evaluating men with suspected persistent or recurrent disease (i.e., with biochemical failure), but with negative or equivocal conventional re-staging imaging (bone scan [BS] and computed tomography [CT] of abdomen and pelvis).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Able to read and speak in English and provide informed consent
- •Male, Age ≥ 18 years
- •Prior primary treatment for prostate cancer with curative intent such as radical prostatectomy or radiotherapy for localized prostate cancer or other local or focal ablative therapy of the prostate
- •Not currently on systemic therapy (adjuvant or salvage) including androgen deprivation therapy
- •Suspected progressive or persistent disease after primary treatment for prostate cancer and biochemical failure (BF) with current management according to the following:
- •Following primary radical prostatectomy (with or without adjuvant or salvage radiotherapy to the prostate bed/pelvis), where BF is defined as rising PSA on at least 2 occasions measured at least 1 month apart and with the most recent PSA measured within 3 months prior to enrollment at > 0.1 ng/mL
- •Following primary radiotherapy (with either brachytherapy, external beam radiotherapy or combined brachytherapy and radiotherapy) for localized disease, where BF is defined according to the Phoenix Definition, which is rising PSA on at least 2 occasions measured at least 1 month apart and with the most recent PSA measured within 3 months prior to enrollment greater than the nadir PSA + 2.0 ng/mL
- •Following primary ablative therapy to the prostate given with radical intent such as prior HIFU (high intensity focused ultrasound) or cryotherapy or other ablative energy therapy with biochemical failure as defined by the Stuttgart Criteria (nadir PSA + 1.2 ng/mL within 3 months prior to enrollment )
- •If PSA > 10 ng/mL, conventional imaging consisting of bone scan and CT scan within 3 months prior to consent that is either negative or equivocal.
- •Male subjects must be either:
- •Documented by medical records or physician's note to be surgically sterile or,
- •If capable of fathering a child, commit to the use of a barrier method of contraception, or agree to remain abstinent for 48 hours post-administration of the IP
- •Male subjects must agree to not donate sperm for 48 hours post-administration of the IP
- •Willing to participate in the study, is expected to be compliant, able to cooperate with study procedures, and have a high probability of completing the study in the opinion of the investigator
- •Vital sign results at Visit 1 and (pre-IP administration) at Visit 2 are within normal ranges, or if outside the normal ranges the results are judged by the investigator to not be clinically significant
- •Karnofsky performance status 70 or better (ECOG 0, 1)
- •Life expectancy of 6 months or more as judged by the investigator
- •Patient is medically suitable for salvage therapies
排除标准
- •Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components
- •Prior PSMA PET scan within 6 months of enrolment
- •Use of any other investigational medication or devices within 30 days prior to Visit 1
- •Known allergies or sensitivity to any component of the investigational product used in this study
- •Received significant ionizing radiation exposure, as judged by the Investigator, including from diagnostic or therapeutic radiopharmaceuticals used in clinical trials or for routine medical examinations, in the last 12 months
- •Undergoing ongoing occupational monitoring for radiation exposure
- •Clinically active, unstable, serious, life-threatening medical condition or disease that is, in the opinion of the Investigator, inadequately treated and/or where study participation may compromise the clinical management of the subject, or any other reason that makes the subject unsuitable to participate in this study
- •The participant has a history of alcohol or substance abuse
- •Patient cannot lie still for at least 30 minutes or comply with imaging procedure
结局指标
主要结局
Primary Endpoint:
时间窗: 8 months
• Imaging concordance (sensitivity, specificity, PPV, NPV) will be calculated by comparing presence or absence of disease based on PSMA-PET (at the patient level) compared with clinical outcome information (e.g., conventional imaging, clinical outcome surrogate or histopathologic correlate)
次要结局
- Percentage of patients identified with recurrent disease using [18F]PSMA-1007(2 months)
- Frequency with which [18F]PSMA-1007 PET/CT results lead to a change in recommended management(2 months)
- Safety: Occurrence of AEs, SAEs, and changes from baseline in vital signs(2 days)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) InhibitorsHemophilia ANCT02795767Hoffmann-La Roche88
已完成
3 期
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal MalesAdult Male HypogonadismNCT02149264Ferring Pharmaceuticals160
已完成
3 期
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia AHemophilia ANCT03020160Hoffmann-La Roche48
招募中
3 期
[18F]PI-2620 Phase 3 Histopathological StudyAlzheimer DiseaseNCT05641688Lantheus Biosciences Ltd.200
进行中（未招募）
3 期
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical CancerCervical CancerNCT04906993Jiangsu HengRui Medicine Co., Ltd.443